This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Dyrskjøt, L. Articles by Ørntoft, T. F. PubMed PubMed Citation Articles by Dyrskjøt, L. Articles by Ørntoft, T. F.

Genomic Profiling of MicroRNAs in Bladder Cancer: miR-129 Is Associated with Poor Outcome and Promotes Cell Death In vitro

¹ Molecular Diagnostic Laboratory, Department of Molecular Medicine, and ² Department of Urology, Aarhus University Hospital; Departments of ³ Molecular Biology and ⁴ Theoretical Statistics and Mathematical Sciences, University of Aarhus; ⁵ Institute of Pathology NBG, Aarhus Hospital, Aarhus, Denmark; ⁶ Wilhelm Johannsen Centre for Functional Genome Research, Department of Cellular and Molecular Medicine, Copenhagen, Denmark; and ⁷ Santaris Pharma, Hørsholm, Denmark

Requests for reprints: Lars Dyrskjøt, Molecular Diagnostic Laboratory, Department of Molecular Medicine, Aarhus University Hospital, Skejby, DK-8200 Aarhus N, Denmark. Phone: 45-8949-9420; E-mail: lars{at}ki.au.dk.

Key Words: bladder cancer • miRNA • diagnosis • prognosis • disease progression

microRNAs (miRNA) are involved in cancer development and progression, acting as tumor suppressors or oncogenes. Here, we profiled the expression of 290 unique human miRNAs in 11 normal and 106 bladder tumor samples using spotted locked nucleic acid–based oligonucleotide microarrays. We identified several differentially expressed miRNAs between normal urothelium and cancer and between the different disease stages. miR-145 was found to be the most down-regulated in cancer compared with normal, and miR-21 was the most up-regulated in cancer. Furthermore, we identified miRNAs that significantly correlated to the presence of concomitant carcinoma in situ. We identified several miRNAs with prognostic potential for predicting disease progression (e.g., miR-129, miR-133b, and miR-518c*). We localized the expression of miR-145, miR-21, and miR-129 to urothelium by in situ hybridization. We then focused on miR-129 that exerted significant growth inhibition and induced cell death upon transfection with a miR-129 precursor in bladder carcinoma cell lines T24 and SW780 cells. Microarray analysis of T24 cells after transfection showed significant miR-129 target down-regulation (P = 0.0002) and pathway analysis indicated that targets were involved in cell death processes. By analyzing gene expression data from clinical tumor samples, we identified significant expression changes of target mRNA molecules related to the miRNA expression. Using luciferase assays, we documented a direct link between miR-129 and the two putative targets GALNT1 and SOX4. The findings reported here indicate that several miRNAs are differentially regulated in bladder cancer and may form a basis for clinical development of new biomarkers for bladder cancer. [Cancer Res 2009;69(11):4851–60]

This article has been cited by other articles:

				E. R. Mardis and R. K. Wilson Cancer genome sequencing: a review Hum. Mol. Genet., October 15, 2009; 18(R2): R163 - R168. [Abstract] [Full Text] [PDF]